Academic Journals Database
Disseminating quality controlled scientific knowledge

Current strategies to minimize the bleeding risk of warfarin

Author(s): Snipelisky D | Kusumoto F

Journal: Journal of Blood Medicine
ISSN 1179-2736

Volume: 2013;
Issue: default;
Start page: 89;
Date: 2013;
Original page

David Snipelisky,1 Fred Kusumoto2 1Department of Medicine, Mayo Clinic, Jacksonville, FL, USA; 2Division of Cardiovascular Diseases, Mayo Clinic, Jacksonville, FL, USA Abstract: For many decades, the vitamin K antagonist warfarin has been the mainstay of treatment for various conditions that require anticoagulation, including atrial fibrillation. Although the efficacy of warfarin in both prevention and treatment of thrombosis has been demonstrated in numerous randomized clinical studies, one of the major concerns that remains is the risk of bleeding. Although the net benefit of warfarin has been demonstrated in large clinical trials, physicians and patients alike are often reluctant to use warfarin because of the bleeding risk. Bleeding in patients on warfarin is generally minor requiring no intervention, but the development of a major bleeding complication is associated with significant morbidity and can even be fatal. Numerous risk factors that increase the probability of having a hemorrhage while on warfarin have been identified, and bleeding risk scores have been developed. Various strategies to reduce bleeding risks have been developed and have become more important, since the use of warfarin and other anticoagulants continues to increase. This paper provides a concise review of bleeding risk factors, while outlining recommendations both physician and patients can incorporate to help reduce the risk of bleeding. Keywords: hemorrhage, warfarin, thrombosis, anticoagulants, dabigatran, vitamin K antagonist

Tango Rapperswil
Tango Rapperswil

     Affiliate Program